| Home | CANCER NOTES: UNDERSTANDING CANCER--jk | CANCER: a Summary in Scientific American | CANCER NOTES: SELECTED IMPORTANT TECHNICAL TOPICS--jk | Signaling that promotes cancer metastasis | Stem cells & deadly cancers--new findings | Bacteria & Cancer--the Complex Ecology | CHEMOBRAIN: Cognifitive impairment from chemotherapy | Drug Treatment of Breast Cancer Questioned--British Study | why chemotherapy increases media survival under 6 months | TOBACCO--NUMBERS OF DEAD AND CAUSES | TOBACCO SMOKE--jk | CHEMICALS FOUND IN TOBACCO AND HEALTH CONSEQUENCES | THE CHEMICAL CAUSE OF CORONARY DISEASE IN SMOKERS | Metastasis, new prophylactic treatment | Cancer risk, standards of evaluation | T-CELL TRIUMPH--success with terminal skin cancer patients | T-cell therapy using modified bacteria | COLON CANCER, an excellent overview | Aspirin & cancer, mechanism, etc. | Coated Aspirin lowers gastric mucosal damage | TERMINAL CANCER--chemotherapy for most types makes little difference | ALTERNATE TREATMENT & INDUCED IMMUNE RESPONSE | 2002 LUNG CANCER STATS | COLON CANCER, sigmoidospy, colonoscopy, & virtual colonoscopy | Basic Facts About Breast Cancer | cancer & methylation
T-cell therapy using modified bacteria

Enlisting a uniquely modified bacteria to stimulate T-cells to attack upon cancer. 


About 1 in a thousand terminally ill cancer patients will miraculously be cured; cured not by medical intervention, but rather by the immune system belatedly being turned on and destroying the cancer.  One woman whom I personally knew thought that her naturalistic remedy of a high radish diet cured her stage-4 ovarian cancer.  For at least 2 decades researches have been attempting to enlist the immune system by the creating of a vaccine uniquely developed from the patient’s cancer cells—the results have been disappointing.  Below is a unique approach to this therapy.


The company doing the research is providing this information--and thus might be overly optomistic. 

09/25/06 -- Today, there are vaccines for a host of diseases, including polio, smallpox, and chicken pox. Administering these vaccines is also as simple and effective as literally giving the patient "a shot in the arm."

In this new era of vaccine development, researchers at a New Jersey-based biotechnology company, Advaxis, Inc., are working on a suite of new vaccines to treat women with different types of cancers, including breast cancer.

Yvonne Paterson, Ph.D., the scientific founder of Advaxis as well as a Professor of Microbiology at the University of Pennsylvania, and her team, have already taken a giant step in the development of a series of cancer- fighting vaccines.

Central to the team's discovery is the microbe Listeria monocytogenes, a bacterium found in dairy products. Dr. Paterson built upon the well-known fact that when Listeria is introduced into the body, it has an extremely powerful, direct stimulatory effect on the activities of immune killer T cells.

By modifying Listeria to deliver cancer antigens, Dr. Paterson was able to direct this response to kill cancer cells. These modified-Listeria vaccines harness the power of the immune system to mount an attack against the Listeria and at the same time, redirect the immune system to also attack the cancer cells.

In early studies, Dr. Paterson used the Listeria bacterium to deliver the tumor-associated protein HER-2/Neu to immune cells. HER-2/Neu is over expressed in 20 to 40 percent of all breast cancers. These cells eventually enlist killer T cells to seek out and destroy the tumor cells that over-express the HER-2/Neu molecule.

The vaccine called Lovaxin B is now in pre-clinical testing. The company is planning on manufacturing sufficient quantities of the vaccine and is seeking FDA approval for a clinical trial.

As a breast cancer survivor herself, Dr. Paterson is committed to the development of cancer-fighting remedies both personally and professionally. Paterson first hit on the idea of using Listeria as a cancer vaccine over ten years ago.

"It took a while to dissect what elements of an immune response were best able to cause the rejection of established tumors," she says. "But it has paid off and we are very excited to see the technology finally being tested in cancer patients."

For more on Advaxis, log on to http://www.advaxis.com.



Enter supporting content here



Disclaimer:  The information, facts, and opinions provided here is not a substitute for professional advice.  It only indicates what JK believes, does, or would do.  Always consult your primary care physician for medical advice, diagnosis, and treatment.